Revenue - For the year ended December 31, 2024, revenue totaled $1.0 million from an upfront license fee related to the Exclusive License and Collaboration Agreement with Kuva Labs, Inc., compared to no revenue in 2023[9] - Revenue for the twelve months ended December 31, 2024, was $1,000, compared to $0 in 2023[22] Operating Expenses - Operating expenses for 2024 were $23.4 million, a decrease of $2.3 million or 8.9% from $25.7 million in 2023[9] - Total operating expenses for 2024 were $23,409, a decrease of 9% from $25,708 in 2023[22] Research and Development Expenses - Research and development expenses were approximately $11.3 million in 2024, down 11.0% from $12.7 million in 2023, primarily due to reduced expenses associated with the Phase 2b ASCEND trial[10] - Research and development expenses decreased to $11,334, down from $12,734 in 2023, representing a reduction of approximately 11%[22] General and Administrative Expenses - General and administrative expenses were approximately $12.1 million in 2024, a decrease of 6.9% from $13.0 million in 2023[11] - General and administrative expenses decreased to $12,075, down from $12,974 in 2023, a decrease of about 7%[22] Net Loss - Net losses for the years ended December 31, 2024, and 2023 were $20.0 million and $20.8 million, respectively[12] - The net loss attributable to Lisata Therapeutics, Inc. common stockholders for 2024 was $19,985, compared to a net loss of $20,840 in 2023, reflecting a reduction of approximately 4%[22] - Basic and diluted loss per share attributable to common stockholders improved to $2.40 in 2024 from $2.58 in 2023[22] Cash and Assets - As of December 31, 2024, cash, cash equivalents, and marketable securities totaled approximately $31.2 million, supporting operations into the second quarter of 2026[13] - Cash, cash equivalents, and marketable securities decreased to $31,245 as of December 31, 2024, down from $50,535 in 2023, a decline of approximately 38%[22] - Total assets decreased to $35,002 in 2024 from $54,694 in 2023, a reduction of about 36%[22] - Total liabilities decreased to $5,685 in 2024 from $6,800 in 2023, a decrease of approximately 16%[22] - Total equity decreased to $29,317 in 2024 from $47,894 in 2023, reflecting a decline of about 39%[22] Clinical Trials and Collaborations - Certepetide has shown a positive trend in overall survival in the ASCEND trial, with four complete responses in the treatment group compared to none in the placebo group[4] - Enrollment in the BOLSTER trial for first-line cholangiocarcinoma was completed nearly six months ahead of schedule, with topline data expected in mid-2025[7] - Lisata has entered into multiple research collaborations, including a partnership with Valo Therapeutics to investigate the combination of certepetide with their platform technology for melanoma treatment[6] Funding - The company received $0.9 million in non-dilutive funding through the Technology Business Tax Certificate Transfer Program, selling $19.6 million in tax benefits for net proceeds of $18.4 million[14]
Lisata Therapeutics(LSTA) - 2024 Q4 - Annual Results